Proteinosis alveolar; nuevas perspectivas: a propósito de dos casos

Iván Noreña, MD.; Nelson Páez E., MD.; Mauricio Durán, MD.; Carlos Aguirre, MD.

doi:10.30789/rcneumologia.v23.n3.2011.214

New outlook on alveolar proteinosis: presentation of two cases

Proteinosis alveolar; nuevas perspectivas: a propósito de dos casos

Published 2011-09-30

Open | Download

PDF (Spanish) FLIP

Issue

Vol. 23 No. 3 (2011)

Section

Presentación de casos

How to Cite

New outlook on alveolar proteinosis: presentation of two cases.

rev. colomb. neumol. [Internet]. 2011 Sep. 30 [cited 2024 Dec. 22];23(3):111-6. Disponible en: https://doi.org/10.30789/rcneumologia.v23.n3.2011.214

DOI

https://doi.org/10.30789/rcneumologia.v23.n3.2011.214

Dimensions

PlumX

license

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Iván Noreña, MD.

Universidad del Rosario. Fundación Cardioinfantil. Bogotá, Colombia.

Nelson Páez E., MD.

Fundación Neumológica Colombiana. Fundación Cardioinfantil, Instituto de Cardiología. Bogotá, Colombia.

Mauricio Durán, MD.

Fundación Neumológica Colombiana. Fundación Cardioinfantil, Instituto de Cardiología. Bogotá, Colombia.

Carlos Aguirre, MD.

Fundación Neumológica Colombiana. Fundación Cardioinfantil, Instituto de Cardiología. Bogotá, Colombia.

Show authors biography

Iván Noreña, MD.,

Residente Medicina Interna. Universidad del Rosario. Fundación Cardioinfantil. Bogotá, Colombia.

Nelson Páez E., MD.,

Neumólogo, Fundación Neumológica Colombiana, Servicio de Neumología, Fundación Cardioinfantil, Instituto de Cardiología. Bogotá, Colombia.

Mauricio Durán, MD.,

Neumólogo, Fundación Neumológica Colombiana, Servicio de Neumología. Fundación Cardioinfantil, Instituto de Cardiología. Bogotá, Colombia.

Carlos Aguirre, MD.,

Neumólogo, Fundación Neumológica Colombiana, Servicio de Neumología. Fundación Cardioinfantil, Instituto de Cardiología. Bogotá, Colombia.

pulmonary alveolar proteinosis

anti-GM-CSF

granulocyte-macrophage colony-stimulating factor

whole-lung lavage

Alveolar proteinosis is a rare respiratory disease characterized by deranged homeostasis of pulmonary surfactant. In most cases, this alteration is caused by antibodies against the granulocyte-macrophage colony-stimulating factor (GM-CSF), which impair the function of alveolar macrophages and bring forth the accumulation of surfactant in terminal air spaces. The diagnostic approach is based on characteristic radiologic findings and histopathological studies. However, serologic diagnosis by measurement of anti-GSM-CSF antibodies to determine an autoimmune origin plays an important role today. The prognosis of this disease is variable. Whole-lung lavage is still the treatment of choice, although alternative therapies such as GM-CSF replacement and other very controversial approaches such as rituximab and plasmapheresis are currently available. We present two cases with different clinical outcomes. These cases lead us to conclude that alveolar proteinosis continues to require research leading to the development of innovative therapeutic interventions.

Article visits 537 | PDF visits 369

Downloads

Download data is not yet available.

Rosen S, Castleman B, Liebow A. Pulmonary alveolar proteinosis. New Eng J Med 1958; 258: 1123-42.
Borie E, Danien C, Debray MP, Taille C, Dombret MC, Aubier M, Crestani B. Pulmonary alveolar proteinosis. Eur Respir Rev 2011; 20 (120): 98-107.
Carey B, Trapnell B. The molecular basis of pulmonary alveolar proteinosis. Clin Immuno 2010; 135: 223-235.
Rossi S, Erasmus J, Volpacchio M, Franquet T, Castiglioni T et al. «Crazy paving» pattern at thin section CT of the lungs: radiologicpathologic overview. RadioGraphics 2003; 23: 1509-19.
Johkoh T, Itoh H, Müller N, Ichikado K, Nakamura H, Ikezoe J, Akira M, Nagareda T. Crazy paving appearance at thin section CT: Spectrum of disease and pathologic findings. Radiology 1999; 211: 155-160.
Trapnell B, Whitsett J, Nakata K. Pulmonary alveolar proteinosis. New Eng J Med 2003; 349: 2527-39.
Seymour J, Presneill J. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med 2002; 166: 215-35.
Luisetti M, Kadija Z, Mariani F, Rodi G, Campo I, Trapnell B. Therapy options in pulmonary alveolar proteinosis. Ther Adv Respir Dis 2010; 4: 239-248.
Michaud G, Reddy Ch, Ernst A. Whole-lung lavage for pulmonary alveolar proteinosis. Chest 2009; 136: 1678-1681.
Beccaria M, Luisetti M, Rodi G, Corsico A, Zoia MC, Colato S, et al. Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis. Eur Respir J 2004; 23: 526-531.
Venkateshiah SB, Yan TD, Bonfield TL, Thomassen MJ, Meziane M, Czich C, Kavuru MS. An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis. Chest 2006; 130: 227.
Wylam M, Ten R, Prakash U, Nadrous H, Clawson L, Anderson. Aerosol granulocyte macrophage colony stimulating factor for pulmonary alveolar proteinosis. Eur Respir J 2006; 27: 55-593.